Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
OCS
OCS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OCS News
Oculis Under Investigation After 23.44% Stock Drop Following Trial Failures
4d ago
Globenewswire
Oculis to Present at Clinical Trials Summit 2026 on Neuroprotective Therapy
Jun 11 2026
Newsfilter
Oculis Under Investigation After 23.44% Stock Drop Following Trial Failures
Jun 09 2026
Globenewswire
Oculis Launches Genotype Trial for Dry Eye Disease
Jun 09 2026
Newsfilter
Oculis Highlights Breakthrough Therapies at Goldman Sachs Healthcare Conference
Jun 08 2026
Newsfilter
Oculis Under Investigation for Securities Violations Affecting Shareholder Rights
Jun 08 2026
PRnewswire
Oculis Holding AG Shares Plunge 23% After Trial Failures
Jun 08 2026
PRnewswire
Nan Fung Group Reduces Oculis Stake
Jun 08 2026
NASDAQ.COM
Nan Fung Group Reduces Oculis Stake Amid Challenges
Jun 08 2026
Fool
Oculis Under Investigation After 23.44% Stock Drop Following Trial Failures
Jun 04 2026
PRnewswire
Oculis Under Investigation for Potential Securities Law Violations
Jun 02 2026
Globenewswire
Oculis Holding AG Faces Major Setback with OCS-01 Program
Jun 01 2026
PRnewswire
Oculis Holding AG Faces 23% Stock Drop After OCS-01 Trial Failures
Jun 01 2026
Newsfilter
Oculis Holding Shares Plunge After Failed Phase 3 Trials
Jun 01 2026
seekingalpha
Oculis OCS-01 Trials Fail to Meet Primary Endpoint
May 31 2026
NASDAQ.COM
OCS-01 Fails to Meet Primary Endpoint in Phase 3 Trials
May 29 2026
stocktwits
Show More News
